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Interest in Traditional Chinese Medicine (TCM) is global. The burgeoning 
international trade in its crude and processed plant ingredients (Chinese 
materia medica - CMM) reflects demand across all sectors of healthcare, yet 
the identification of source plants and CMM has been overlooked for many 
years leading to problems in safety, quality, efficacy and sustainable sourcing.  
The Guide (Chinese medicinal plants, herbal drugs and substitutes: an 
identification guide, Leon & Lin, Kew Publishing, 2017), which forms the core 
of this dissertation by publication, presents a fresh approach to the 
identification of 226 internationally traded CMM (officially recognised in the 
Chinese Pharmacopoeia, CP2015) along with their 302 official source plants.  
  
Identification criteria are developed using macroscopy, and are based on 
authentic reference specimens created as a result of extensive fieldwork in 
China. Inclusion of 99 comparative descriptions of unofficial substitute plants 
and drugs (including adulterants and counterfeits), with their counterparts 
for official species, enable key distinguishing characters to be highlighted and 
thereby strengthen the rigour of identifications made. The approach 
demonstrates that macroscopy can be used to reliably identify and 
differentiate over 70% of official (CP2015) CMM from common substitutes 
and that macroscopy is a fast and cost-effective authentication method with 
many applications.  
The research highlights the essential role of herbarium-vouchered reference 
drugs in CMM authentication as opposed to the use of market-obtained 
drugs whose botanical identity is inherently uncertain. The research’s 
taxonomic review of all official species in the Guide demonstrates a 
significant disparity (16%) between the taxonomy adopted in the CP2015 and 
current plant taxonomic opinion, while a review of species conservation 
rankings and causal effects found that the wild populations of 23% of official 
species native to China (63 of 270 official species in the Guide) have become 
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threatened as a direct result of over-harvesting for medicinal use. In addition, 
the research reveals the underlying causes of CMM substitution are 
dominated by clinician preference, followed by supply problems arising from 
over-harvesting of official species with unregulated markets trading in 
inferior or inappropriate look-alike items, together with issues of confused 
identification and nomenclature. Direct consequences of the inadvertent use 
of CMM substitutes include misleading clinical and research outcomes, 
serious adverse reactions and, in some cases, fatalities. Reliable identification 
of CMM therefore remains paramount for high quality research as well as 
safe and efficacious clinical practice. While for some CMM (ca. 30% of CMM 
in the Guide) robust identification requires analytical methods (e.g. chemical- 
and DNA-based ones), the research concludes that macroscopy continues to 
be a powerful tool for reliable and cost-effective identification of CMM in 
international trade.  
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The Guide refers to my published book ‘Chinese medicinal plants, herbal 
drugs and substitutes: an identification guide’ Leon & Lin, Kew Publishing, 
2017. 
Traditional Chinese Medicine (TCM), dating back over 2,500 years, is widely 
practised in China today as a government-recognised healthcare system 
spanning herbal medicine, acupuncture, massage, exercise and dietary 
therapy.  This term used here and in the Guide refers to its herbal component 
only.   
Chinese materia medica (CMM)/drug: a commercial trade item of one or 
more plant parts derived from one, occasionally more, species (see 
Pharmacopoeia species below) and prepared in line with traditional TCM 
methods (see Guide, p. 9). Each CMM takes the form of a crude (usually 
simply dried) or processed drug (i.e. heat-treated with or without adjuvants). 
Crude CMM are seldom seen outside China (or other source countries) 
because processing is designed (inter alia) to prolong shelf-life and usually 
requires specialist skills best performed in-country. Large CMM (crude and 
processed) are sliced or broken into smaller pieces called Yin Pian (decocting 
pieces) to facilitate release of active principles once in decoction. For CMM 
requiring no processing or slicing (e.g. Ling Xiao Hua, Guide, p.579) the CMM 
is traded in one form only so there is no difference between the crude drug 
and its decocting pieces. See also Table 1. 
Pharmacopoeia species/official species: a plant species recognised by the 
2015 edition of the Chinese Pharmacopoeia (CP2015) as the source of a 
CMM.  
Unofficial substitute: a plant species or CMM used accidentally or 
intentionally as a substitute, contaminant or adulterant not included in the 
CP2015.  This includes certain CMM and their source plants that, although 
widely used in TCM today, are currently excluded from the CP2015 for a 
variety of reasons, plus other accidental or intentional plant substitutes, 
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contaminants and counterfeits (the latter derived from plant or other 
materials).  
Identification versus Authentication:  identification refers to the process of 
identifying a plant or trade items which may or may not already be named, 
whereas authentication is the process of confirming the identity of an already 
named (scientific or other) plant or trade item. The process of authentication 
is therefore a subset of identification and the two terms are used 
interchangeably according to context.  For example, the choice of ‘an 
identification guide’ in the Guide’s title reflects its use for named as well as 
unnamed plant species, CMM and other trade items.   
 
ABBREVIATIONS 
CMM  Chinese materia medica  
CP  Chinese pharmacopoeia 
IUCN  International Union for Conservation of Nature 
RBG Kew    Royal Botanic Gardens, Kew  






The resurgence of plant-based medicines, nutraceuticals and cosmeceuticals 
in the West has yet to be matched by the development of robust herbal 
quality-assurance (QA) systems. This is especially true of QA systems for 
herbal Chinese materia medica (CMM) which represent the bulk of 
ingredients used in Traditional Chinese Medicine (TCM), a therapy practised 
today in over 180 countries (Xinhua, 2016). The rapidly growing global market 
in CMM, estimated in 2012 to be worth US$83.1 billion (WHO, 2013), 
provides the raw ingredients not only for the expanding TCM industry but 
also the booming natural products sectors too. As supply chains struggle to 
keep pace with spiralling demand, this largely unregulated global market is 
vulnerable to rogue practices that has led to concerns about the quality and 
safety of CMM traded notably their correct identity, purity and appropriate 
processing (Shaw, 2010; Chan et al., 2007; Zhang et al., 2012; Zhao et al., 
2010). Lack of CMM reference herbs and limited dialogue between the 
disciplines of TCM and botany worldwide has resulted in poor botanical 
identification protocols across TCM and hampered the design of robust QA 
systems (Bauer & Franz, 2010).  
 
CMM are characterised by i) their high diversity of trade forms, often the 
result of different processing methods (Pao Zhi) such as stir-frying, steaming 
or carbonising); ii) their complex trade nomenclature, often reflecting 
morphological appearance, geographical provenance and/or processing 
methods and iii) their frequent sourcing often from more than one plant 
species (Wu et al., 2007; Zhao et al., 2006b, 2007, 2010). The Chinese 
Pharmacopoeia (2015 edition, hereafter ‘CP2015’) provides official 
specifications of these and other pharmaceutical characters for 506 herbal 
CMM and as such represents the Chinese government standard for these 
entities. The Guide documents 226 of these CMM. Note that the CP2015 has 
yet to develop specifications for all CMM in current use. The use of CMM in 
China can also be split into those destined for inclusion in TCM manufactured 
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products as opposed to those prescribed as loose CMM for use in decoctions 
(the more traditional form of CMM administration). The information 
presented in the Guide is equally relevant to both, and also to those sectors 
using CMM outside the context of TCM.   
Other features of CMM relevant to the present research are i) the origin of 
the source species (ca. 80% wild-harvested; the remainder cultivated on small 
or large-scale medicinal plant farms) and ii) their supply chains (typically long, 
with numerous middle-men and, in the main, poorly regulated) (Booker et al., 
2012; Huang, 2011; Zhang et al., 2010). 
The above factors and inherent complexity of CMM have shaped the design 
of my research and notably the scope and selection of the CMM documented 
and the substitutes, adulterants, contaminants and counterfeits with which 
they have been compared (see Guide, pp.1-9).    
  
1.1 Why is botanical identification of CMM important?  
Identification of source plants underpins not only their use in medicine but 
also other sectors such as conservation and livelihoods. Botanical clarity 
underpins:  
 Efficacy: use of the incorrect species undermines the integrity of 
plant-based medicines. 
 Safety: well-documented cases of adverse reactions owing to plant-
based medicines could have been prevented with better 
understanding of the identity of the source plants (Shaw, 2010).  
 Conservation: development of conservation plans, including medicinal 
crop production, is reliant upon the correct choice of plant species.  
 Livelihoods: a broad range of stakeholders ranging from local 
communities to industry benefit from production of plant-based 




1.2 Research questions 
The over-arching aim of my research is to bring botanical clarity to the 
morphological identification of the official (CP2015) source plants officially 
used in TCM, and their commercially-traded CMM. Four main research 
questions underpin the work: 
1. To what extent can macroscopic characters reliably differentiate 
official CMM from their common unofficial substitutes?  
2. What is the taxonomic alignment of the current Chinese 
Pharmacopoeia (CP2015) with current taxonomic opinion, and how 
has this affected my circumscription of CMM?  
3. What are the drivers underlying the occurrence of unofficial CMM 
substitutes in international trade?  
4. To what extent does medicinal harvesting impact the conservation 
status of source plants? 
 
2. CONTEXT 
2.1 An interdisciplinary approach 
The literature consulted spans the disciplines of TCM (specifically drug 
identification, sourcing, processing and trade nomenclature); plant taxonomy 
and nomenclature; herbal medicine safety, regulation and 
pharmacovigilance, and species conservation. My access to literature in 
Chinese has been limited due to the language barrier, but has been 
circumvented in part by use of journal translation databases (e.g. the China 
National Knowledge Infrastructure database (CNKI)) and in part by working 
with my Chinese co-author Lin Yu-Lin.  
Cornerstone texts include the Chinese Pharmacopoeia (2010 English edition 
and 2015 Chinese edition) with pharmaceutical specifications for 506 official 
CMM; Modern Chinese Materia Medica (Xiao et al., 2001-02); Guangdong 
Pharmacopoeia (Lin, 1990-96); Chinese Herbal Medicine: Materia Medica 
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(Bensky et al., 2004) and Pharmacology and Applications of Chinese Materia 
Medica (Chang & But, 1987).  
Key taxonomic and nomenclatural resources accessible on-line include the 
Flora of China (1994–2013) with over 31,000 plant taxa, and Medicinal Plant 
Names Services which provides access to ca. 300,000 scientific and non-
scientific plant names. 
2.2 CMM identification literature 
CMM scientific publications since the 1980s have largely focused on the 
application of chemical analytical methods to pharmacological activity, and 
chemical markers for quality control and identification (Razmovski-
Naumovski et al., 2010; Li et al., 2008; Kite et al., 2003). The vast 
phytochemical literature that followed includes monographic works such as 
Wagner et al. (2011-15) Chromatographic fingerprint analysis of herbal 
medicines and Wang et al. (2013) Monographs for Quality Evaluation of 
Chinese Crude Drugs. Although specific to CMM, the application of these 
identification methods has proven limited since few marker compounds are 
species specific, and many are destroyed during CMM processing (Xie & 
Leung, 2009).  
Given that TCM is an actively evolving medical system, temporal changes in 
CMM drug definitions have inevitably arisen between editions of the Chinese 
Pharmacopoeia over its 57 year history (Hao & Jiang, 2015). Prior to the 
CP1997 edition, for example, ‘Wu Wei Zi’, was officially sourced either from 
Schisandra chinensis or S. sphenanthera but subsequent editions define the 
latter as a separate drug called ‘Nan Wu Wei Zi’ (Guide, pp. 686-7, 742-5). An 
awareness of these evolving definitions is essential when interpreting the 
wider literature. Thankfully there has been a trend towards one drug – one 
species in recent CP editions but despite this, the market place presents a 




The effects on patient safety of the use of an unofficial substitute are often 
difficult to evaluate because CMM are typically used as multi-ingredient 
formulae of 5-15 herbs. Each formulation is prepared according to TCM 
principles with each ingredient performing a specific function when combined 
with others. Their substitution can disrupt a formula’s delicate balance 
rendering it, at best, ineffective and at worst, harmful. For example, the 
potential toxicity of many CMM on their own is modulated when decocted 
with others. The pharmacokinetic interactions of these formulae is therefore 
complex and presents a huge challenge to their toxicological investigation 
(Shaw, 2010).  
The most well-known series of adverse reactions occurred in Belgium in the 
1990s with 112 patients diagnosed with acute renal failure over a 5 year 
period. The causative plant was proven to be Aristolochia fangchi (see ‘Fang Ji 
– Stephaniae Tetrandrae Radix’, Guide, page 124-9) owing to its content of 
aristolochic acids which are well documented to be both nephrotoxic and 
carcinogenic. The cause of the substitution was thought to be due to confusing 
trade names, coupled with the use of the plant outside its TCM context (Wu et 
al., 2007).  
Although the Guide includes safety information, where available, on a CMM-
by-CMM basis, a detailed analysis of the implications of inaccurate species 
sourcing, poor processing or intentional substitution along the supply chain is 
beyond the scope of this thesis. The Aristolochia case series (above) 
illustrates the time and level of expertise required to thoroughly investigate 
cases of adverse reaction (Shaw, 2010).  
2.4 Novelty of my work 
With my research designed to bring botanical rigour to the CMM trade in 
Europe, several features, especially in combination, set my Guide Chinese 
medicinal plants, herbal drugs and substitutes: an identification guide apart 
from other texts:  
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 exhaustive use of fully validated CMM (i.e. cross-referenced to 
herbarium vouchers as opposed to market samples of unknown 
provenance);  
 taxonomic and nomenclatural alignment of plant species with current 
world taxonomies; 
 semi-technical plant descriptions written from scratch for audiences 
with minimal botanical training;  
 wild versus cultivated source information;  
 CMM substitutes selected from first-hand knowledge of field and 
markets in China and the UK focusing on substitutes known to occur in 
international trade;  
 in-depth comparative descriptions and photographs of Chinese 
Pharmacopoeia CMM (2010; 2015) and their substitutes plus their 
equivalents for source plants;  
 an interdisciplinary approach integrating information sets across many 
disciplines with, for CMM substitutes, a substitution comment giving a 
rationale for the likely cause of substitution;  
 safety summaries;  
 conservation and protected species status.  
 
3. SCOPE AND METHODOLOGY  
3.1 Coverage  
Estimates of numbers of medicinal plant species native to China have ranged 
from ca. 5,100 (Xiao, 1991) to over 8,000 (Hamilton, 2004; Huang, 2011) and, 
most recently, to 10,000-11,250 (Pei & Huai, 2015). The 506 CMM listed in 
the CP2015 represent the mainstream herbal drugs used specifically in TCM 
(as opposed to those used by China’s ethnic minorities and others in ad-hoc 
folk medicines).  
Criteria for selection of 226 CMM are covered in the Guide’s Introduction (p. 
2) and represent 45% of CP2015 CMM. Where trade substitutes have been 
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detected, comparative descriptions are provided, including their source 
plants. See the Guide (pp. 5-11) for an overview of the supporting 
information provided for each CMM account.  
3.2 Reference materials for official CMM and their unofficial substitutes1 
Underpinning the whole Guide, and illustrated throughout, is a set of ca. 
1,300 vouchered CMM reference drugs. These have resulted from my field 
collecting programme of 14 field expeditions across 21 provinces of China 
between 1998-2014 (see Introduction and Expedition Map, Guide, pp. 2-3). 
Representing crude and processed drugs and their decocting counterparts 
they are complemented by an equivalent set of materials for substitutes.  
The important role of these reference materials in ensuring plant and CMM 
identification rigour throughout the research cannot be overestimated. These 
collections have been regularly consulted to help resolve adverse reactions 
implicating TCM herbs, notably as part of a joint Kew-Guy’s Hospital 
Traditional Medicines Surveillance Programme (Perharic et al., 1995; Shaw et 
al., 1997) and for the WHO Adverse Drug Monitoring Centre (Farah et al., 
2000, 2006). They have also been used to provide physical reference 
materials for chemical and DNA-based authentication research undertaken by 
Kew and the Institute of Medicinal Plant Development (IMPLAD) (Chen et al., 
2010, 2014; Kite et al., 2002, 2003, 2009). 
3.3 Substitutes 
The causes underlying the occurrence of each substitute have been 
investigated on a case-by-case basis using both the literature and first-hand 
field experience of CMM along their supply chains (mostly in mainland China, 
Hong Kong, Taiwan and the UK). Conclusions are summarised in a species-
specific Substitution Comment alongside each substitute in the Guide (e.g. 
Ban Lan Gen, Guide, p. 48). This approach aims to inform future directions in 
herbal research, regulation and practice.  
                                                          
1 see definition of ‘unofficial substitute’ p. vii  
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3.4 Choice of CMM identification technique 
Despite macroscopy persisting as the main quality-control tool of CMM today 
(Zhao et al., 2011) comparative macroscopic research has been neglected in 
recent years (Leon, pers. obs. 2010-present), due largely to limited availability 
of reliable reference drugs and substitutes. Overcoming this limitation has 
been possible by ready access to my purpose-made reference materials 
(section 3.2). Although chemical and DNA-based techniques were originally 
considered as additional identification techniques for inclusion in the Guide, 
the expense needed in time, materials and their comprehensive application 
would have severely limited the number of species included making the 
Guide less representative of the scope of the substitution problem currently 
facing the international CMM market.  
3.5 Botanical taxonomy and nomenclature 
The TCM and associated Chinese literature abounds with much ambiguous 
scientific taxonomy and nomenclature. I have invested much effort, 
therefore, in its alignment (not a routine task) with current global plant 
taxonomic opinion notably using the Flora of China (FoC), the World Checklist 
of Selected Plant Families (WCSPF) and the Medicinal Plant Names Services 
(MPNS; Guide, p. 6). For resolution of occasional but especially challenging 
names I have drawn on the expertise of specialist taxonomists at the RBG 
Kew.  
3.6 CMM nomenclature 
CMM nomenclature is notorious for its complexity and an understanding of it 
is vital to bridge the botanical/TCM divide (see Table 1). Perhaps most 
fundamental is that a single CMM is frequently sourced (officially, cf. CP2015) 
from more than one plant species. Latin pharmacopoeia names (e.g. 
Scrophulariae Radix) are frequently confused with Latin botanical names.  
Chinese characters are used either in their simple or traditional forms; the 
latter are routinely used in Taiwan and other S.E. Asian countries where TCM 
is practised. Mainland China predominantly uses simplified characters. 
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3.7 Limitations  
The prescriptive design of the Guide sometimes limited space, especially for 
Substitution Comments which frequently had to be condensed, while 
compromises also had to be made on the size and choice of CMM 
photographs and their close-ups. See also section 3.4. 
 
4. RESEARCH QUESTIONS 
4.1 To what extent can macroscopic characters reliably differentiate official 
CMM from their common unofficial substitutes? 
4.1.1 Introduction & literature review 
The macroscopic approach to CMM identification has been a feature of 
Chinese herbal texts (Ben Cao) dating as far back as 168 BCE (Zhao and Chen, 
2014). Modern literature from the 1950s onwards has seen microscopy and, 
subsequently, chemical and DNA methods come to the fore. Modern 
analytical chemical methods (e.g. HPLC1, LC-MS-MS2 and GC-MS3) have a role 
to play in finger-printing and detecting reliable marker compounds but cost, 
turn-around times and scarcity of interpretation expertise are limitations.  
The robustness of DNA barcodes require careful interpretation 
(Hollingsworth et al., 2011) although, for the first time, have been included in 
the current edition of the Chinese Pharmacopeia (CP2015). The advent of 
whole genome sequencing and other omic techniques may deliver 
authentication solutions in time but their interpretation and application are 
still at an early stage (Buriani et al., 2012).  
In the meantime, CMM macroscopic identification texts have continued to 
hold their own with some 100 illustrated texts published during this same 
period (1950s onwards). This is the specialist field most closely aligned with 
my own. Predominantly written in Chinese, these texts tend to be 
                                                          
1 HPLC: high performance liquid chromatography   
2 LC-MS: liquid chromatography–mass spectrometry 




significantly narrower in their information coverage for individual CMM, 
comparative descriptions of common substitutes is usually absent and, most 
significantly, verification of the identity of the source plants is totally lacking. 
The 7-volume Taiwanese text ‘Good quality Chinese materia medica’ (Zhang, 
2008) demonstrates the widest coverage of CMM types but, despite its 
wealth of high quality CMM photographs, is inaccessible to non-Chinese 
readers with captions entirely in Chinese and Latin botanical names deeply 
hidden in other cross-referenced volumes. Its closest rival for breadth of 
CMM is the lllustrated dictionary of Chinese herbal medicines (NICPBP, 1997-
2002), valuable for its inclusion of substitutes but the CMM illustrated often 
resemble aged museum materials atypical of those likely to be encountered 
in today’s markets. Only Ho et al. (2006), also from Taiwan, attempt a 
comparative approach, targeting a small number of CMM (60); its simple 
design serves as a quick reference for market traders and, as such, 
complements the above texts but once again the complete lack of evidence 
about the identity of the source plants undermines its scientific relevance. 
Among the scarce English texts in this field (ca. 12 in total) most authoritative 
are the American Herbal Pharmacopeia monographs (with in-depth 
analytical, quality control and therapeutic information but sadly limited to 
only eight CMM; cited in the Guide under Upton) and Zhao & Chen’s (2014) 
Chinese Medicinal Identification spanning 429 CMM. While the latter text 
includes twice as many CMM as in the Guide, the recurring issue of lack of 
evidence of source plant identity undermines its scientific integrity. Other 
limitations are Zhao & Chen’s minimalist approach to information content, 
omitting botanical descriptions, wild/cultivated provenance, conservation 
status of source plants (and their substitutes), drug substitute comparisons 
and safety, and only passing references to processing types are made; neither 
is there any attempt to bring botanical clarity to the taxonomy and 
nomenclature of the source plants. Finally the style of CMM decocting pieces 
(Yin Pian) illustrated are more typical of those popular on the Hong Kong 
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market rather than those found in international trade and are, therefore, less 
helpful as identification aids to these wider audiences.  
4.1.2 Results 
The major focus of the Guide is discrimination of unofficial substitutes, of 
which 99 are described in detail. For the reasons explained in sections 2.3 and 
3.3 their detection is vital. The Guide demonstrates that 72% of these 
unofficial substitutes can be reliably detected macroscopically from their 
official counterparts. Examples include the detection of florets of ‘Hong Hua’ 
(Carthamus tinctorius) from its high-value official CMM ‘Xi Hong Hua’ (style 
and stigma of Crocus sativus, Guide, pp. 596-9), and the detection of ‘Jia Ma 
Chi Xian’ (aerial parts of Bacopa monnieri) from official ‘Ma Chi Xian’ (aerial 
parts of Portulaca oleracea, Guide, pp. 368-71). An additional 11% of 
unofficial substitutes can be detected in their crude form only. For example, 
the crude drug of ‘He Shou Wu’ (Fallopia multiflora) can be distinguished 
from that of its unofficial substitute sourced from F. aubertii (Guide, pp. 156-
7), however when processed with black soya bean juice, the two are 
indistinguishable (pp. 158-9). 
The remaining 17% of unofficial substitutes cannot be differentiated from 
their official CMM in either crude or processed forms. An example of a CMM 
requiring ‘validation’ with other methods is ‘Chuan Mu Tong’ (Clematidis 
Armandii Caulis, Guide, pp. 428-33) where reliable differentiation of the 
pharmacopoeia species Clematis armandii and C. montana from the unofficial 
substitute (stem of Aristolochia manshuriensis) is imperative for legal and 
safety reasons. This substitute is banned in most countries owing to its 
cumulative nephrotoxicity (Debelle et al., 2008).  
 4.1.3 Discussion 
The question arises as to whether the relatively high proportion of 
substitutes that can be differentiated macroscopically is representative of the 
wider CMM market. There are insufficient data to argue that this pattern is 
representative of all CMM, but conscious bias in favour of more easily 
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separated CMM can be ruled out. Several criteria were used for inclusion of 
CMM in the Guide (p. 2) but did not include likelihood that macroscopic 
identification would prove to be robust; this was only evaluated after 
macroscopic characterisation was carried out. 
Even when macroscopic differentiation is considered ‘reliable’ it is 
nevertheless an end-user’s decision as to whether or not further validation 
using other methods is required based on context (e.g. the dispensing of a 
CMM by a TCM clinic for a patient’s prescription, the preparation of a quality 
control dossier for a formal application for Traditional Herbal Registration, or 
seizure by a customs officer of an international trade consignment potentially 
in breach of CITES).  
Results indicate that the degree of processing of CMM is a major factor in 
determining whether macroscopy is a robust identification method. Species 
determination is therefore best performed on CMM prior to processing when 
identification characters are not yet obscured. 
4.1.4 Conclusions 
Despite the advent of laboratory-based methods, the macroscopic method 
continues to be a powerful identification tool for many CMM. The power of 
macroscopy is validated in the Guide through its comparative approach, 
based on consistent character-by-character differentiation. This approach 
assessed the robustness of macroscopy on a drug-by-drug basis and, where 
appropriate, recommends the use of other methods.  
 
4.2. What is the taxonomic alignment of the current Chinese 
Pharmacopoeia (CP2015) with current taxonomic opinion, and how has this 
affected my circumscription of CMM? 
4.2.1 Introduction & literature review 
In the absence of a single, comprehensive and up-to-date global taxonomy 
for plants, the Guide has aimed to reflect current plant taxonomic opinion by 
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mapping Latin botanical names to those accepted in FoC, WCSPF and MPNS. 
The taxonomic rationale for choice of Latin botanical names in the Chinese 
Pharmacopoeia is less precise; the main taxonomic sources are cited as the 
‘Flora of China [FoC] and Higher Plants of China etc.’ but the preface of 2015 
edition states that ‘Latin names have [been] subsequently regulated and 
revised’. Such taxonomic ambiguity,  perpetuated between all editions of the 
CP, has not only been a cause of confusion to the TCM community as whole, 
but has often required considerable research during production of the Guide 
and invariably resulted in some taxonomic mis-alignment between the 
CP2015 and the Guide.  
4.2.2 Results 
84% of Latin botanical names in the CP2015 have been adopted as accepted 
names in the Guide because they reflect current taxonomic consensus. The 
remainder have been treated as synonyms, or otherwise noted. All 
discrepancies are given under Taxonomic/nomenclatural notes for each 
species in the Guide. These have occurred at family, genus and species levels.  
4.2.3 Discussion 
Unlike many CMM specialists, my workplace at RBG Kew has provided me 
with an awareness of the development of a global plant taxonomy and the 
importance of mapping Latin botanical names through resources such as the 
MPNS. In an effort, to align the CP2015 Latin scientific names with this global 
aim, I have made three main types of taxonomic adjustment: 
 Change in genus or species delimitation: this includes ‘lumping’ of 
taxa as one, or changes in generic circumscription. An example of the 
former is ‘Xi Xian Cao – Siegesbeckiae Herba’ (Guide, pp. 396-9) with 
the three CP2015 taxa reduced to one (Sigesbeckia orientalis) with a 
concomitant change in its genus spelling from Siegesbeckia to 
Sigesbeckia. On this occasion, a taxonomic view in the Flora of Japan 
was followed in preference to that of FoC or MPNS for reasons 
explained in the text. An example of change in genus is illustrated by 
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the drug ‘Wu Jia Pi’, Acanthapanax gracilistylus, now regarded as 
Eleutherococcus nodiflorus (Guide, p. 526). 
 Re-identification of source taxa: in three cases, use of my reference 
collections of herbarium-vouchered CMM resulted in the re-
identification of source plants.  For example, the identity of the source 
plant of the important drug ‘Shan Yao’ was found to be Dioscorea 
polystachya rather than the CP2015’s D. opposita (Guide, p. 268). 
Re-examination of material widely called Cistanche tubulosa, one of 
the parasitic source species of ‘Rou Cong Rong – Cistanches Herba’, 
has resulted in what appears to be an undescribed species and which, 
owing to its host-specificity to the genus Tamarix, my co-author and I 
have provisionally named Cistanche ‘Tamarisk’ (Guide, p. 470). I 
acknowledge here the taxonomic advice of Michael Gilbert (Missouri 
Botanical Garden).  
 Ambiguous definition of type subspecies. For example, for ‘Hou Po’ 
(Guide, p. 508), the CP2015 omits the type varietal name ‘var. 
officinalis’ for Magnolia officinalis. In this and other cases it is unclear 
whether the CP2015 refers to all infra-specific taxa or just the type 
variety. Where ambiguity remains this has been noted in the Guide’s 
‘taxonomic/nomenclatural notes’ for each CMM. 
Nomenclatural errors in CP2015, e.g. in spelling and author names, were very 
frequent and often took considerable time to resolve.  
As argued for macroscopic research (see 4.1.3), the taxonomic findings just 
described are likely to be representative of wider CMM. No conscious effort 
was made to select taxonomically problematic CMM in the Guide. 
4.2.4 Conclusion 
Results of the taxonomic approach adopted throughout (see section 3.5) 
demonstrate an alignment of over 80% between Latin botanical names used 
in the Guide and CP2015. In the remaining cases where names are 
ambiguous, work carried out on the Guide demonstrates that resolution of 
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these names requires specialist taxonomic expertise. The implication for 
CMM herbal quality control is that both industry and regulators require cross-
sector collaboration with taxonomic institutes. 
 
4.3. What are the drivers underlying the occurrence of unofficial CMM 
substitutes in international trade?  
4.3.1. Introduction & literature review 
The accidental or intentional occurrence of unofficial herbal substitutes 
(which includes clinical substitutes, adulterants, contaminants and 
counterfeits) is well-known among experienced TCM scholars, traders and 
practitioners but is poorly understood in the West. This is because i) the 
vastness and complexity of the global CMM trade makes these substitutes 
difficult to investigate systematically; ii) patterns of substitution change over 
time and space and iii) although their detection is often straightforward their 
identification is not. Furthermore, Understanding the current drivers of CMM 
substitution can help pre-empt their detection and management. Section 3.3 
summarises the approach used here for their investigation.  
The seminal book Chinese herbal medicine materia medica (Bensky et al., 
2004) is the first English text to list scientific names of ‘alternate species’, 
‘local variants’ and ‘adulterants’ according to historical TCM texts. The review 
paper by Zhao et al. (2006a) presents one of, if not the only attempt in 
English to classify the origin of CMM substitutions, in this case, on the Hong 
Kong market. The only identification study specific to CMM traded in the UK 
is the recent work on fruits and seeds by van der Valk et al. (2017) which 
provides detailed discussions on the substitutes encountered in market 
sampling of 20 CMM.  
4.3.2. Results 
The 226 CMM described in the Guide represent 45% of those in the CP2015. 
Of these 226, 85 (38%) are reported to experience regular substitution (based 
on first-hand knowledge) when traded in international markets. A brief 
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analysis of causal factors presented in the Guide (under ‘Substitution 
Comment’) is shown in Table 2.  
4.3.3. Discussion 
Examples of each of these causes of substitution are analysed below: 
i) Clinical similarity/interchangeable use   
This refers to the intentional use of a drug that has similar clinical properties 
to the official drug and which is used either out of clinical preference, or 
because of its easy availability, or for a combination of all three. Such local 
substitutions are typical in China and hark back to an earlier era when China’s 
vast distances meant there was a greater reliance on locally available herbs. 
For example ‘Ban Lan Gen’ (Isatidis Radix) is sourced in northern China from 
Isatis tinctoria, but in southern China is from Strobilanthes cusia (Guide, p. 48). 
A case of international substitution is ‘Mu Xiang’ (Aucklandiae Radix, Guide, pp. 
210-9): the original source was the root of the Chinese native Inula helenium; 
this has been replaced by Aucklandia costus imported from the Indian 
Himalayas, which is considered to have superior clinical properties. 
Clinical substitutions such as this represent by far the largest cause of 
substitution.  
ii) Supply problems 
Declining herbal resources are a product of many factors including booming 
world trade, new medical needs and climate change. The over-harvesting of 
‘Shan Dou Gen’ (Sophorae Radix, Guide, pp. 260-3) sourced from the root of 
Sophora tonkinensis to treat China’s rising incidence of throat cancer has led 
to its near extinction in the wild. In the absence of its successful cultivation the 
market has moved to an inferior substitute ‘Bei Dou Gen’ (Menispermi 
Rhizoma, Guide, p. 60, root of Mensipermum dauricum) another TCM herb in 





iii) Mis-identification at point of harvest 
Wild harvested species may be prone to mis-identification with 
morphologically similar species (often close relatives) which grow in close 
proximity. An example is the inadvertent substitution of ‘Ma Chi Xian’ 
(Portulacae Herba, Guide, pp. 368-71) with the totally unrelated but similar-
looking (especially when not in flower) Bacopa monnieri (Guide, pp. 370-1). In 
contrast, species sourced from cultivated sites are by their nature predictable 
because of planned planting and management regimes. This is illustrated in 
CMM sampled from selected TCM outlets in the UK (van der Valk et al., 2017): 
95% of samples derived from cultivated plants (n = 103) were sourced from an 
official species; this contrasts with 78% from wild plants (n = 64). 
iv) Confused Chinese trade nomenclature      
With some 10,000-11,250 medicinal plant species in China, shared vernacular 
names are inevitable. For example, the vernacular trade name ‘王不留行 Wang 
Bu Liu Xing’ (Guide, pp. 732) is used for at least two CMM derived from 
completely different species. The CP2015 uses this name to refer to the seed 
of Vaccaria hispanica (Caryophyllaceae, Vaccariae Semen, Guide, p. 732) while 
in south China the identical name is widely used for the CMM derived from the 
fruit of Ficus pumila (Moraceae). Fortunately these two CMM are 
macroscopically very distinct, as are their therapeutic properties. Regional 
substitutions of this kind permeate CMM trade in China but owing to the much 
smaller numbers of CMM traded internationally, examples of such potential 
confusion are rare.  
v) Cheaper morphological look-alikes for high-value drugs  
Economic incentives for the use of cheap substitutes has a long history in 
herbal medicine. The market for American ginseng (Panax quinquefolius), for 
example, is regularly adulterated with cheap morphologically similar 
substitutes such as ‘Dang Shen’ (roots of Codonopsis pilosula in the 




The selection of CMM in the Guide focused on patterns of substitution in 
international trade hence the incidence of substitutions encountered in the 
Guide is not representative of the wider TCM trade. In contrast, the drivers of 
substitution is likely to be representative of the wider trade.  
Researching substitution patterns and their causes presented one of the most 
challenging aspects of preparing the Guide, requiring a detailed understanding 
of individual species (such as wild versus cultivated sourcing and conservation 
status) as well as supply and demand issues of their commercially traded CMM. 
Factoring these research results into herbal quality assurance systems has 
considerable potential to improve their cost-effectiveness as well as ensure 
they are fit-for-purpose. Herbal substitution research of this kind, however, is 
acutely under-studied and requires urgent multidisciplinary support (van der 
Valk et al., 2017).  
 
4.4. TO WHAT EXTENT DOES MEDICINAL HARVESTING IMPACT THE 
CONSERVATION STATUS OF SOURCE PLANTS? 
4.4.1 Introduction & literature review 
Since the 1960s, China’s flora has been subjected to the onslaught of China’s 
extensive economic development boom with its highly damaging 
environmental fall-out such as large-scale deforestation, road construction, 
urbanisation, intensive agriculture not to mention globalisation of its TCM 
industry leading to spiralling demand for its medicinal resources (Huang, 
2011). With ca. 80% of TCM plant species wild-sourced (Zhang et al., 2010) 
they are especially vulnerable to all of these pressures.  
China’s nationwide survey of TCM natural resources from 1983-1994 (Xu et 
al., 2013) provides a backdrop for conservation. Assessing the conservation 
status of medicinal plants species, however, in a country the size of China and 
with a flora of over 31,000 species is a challenge; figures are at best 
provisional. The international Red-Listing programme (managed by IUCN) is 
19 
 
slow to validate recommendations for species to be listed, such that a species 
that is absent from this global list is not necessarily out of danger. This is 
where national red-listing initiatives come into their own as interim indicators 
of threat. For example, Fu (1992) drew attention to some 25 threatened 
medicinal plant species in China’s first plant red data book; 21 of these are 
described in the Guide. A flurry of much lengthier red lists swiftly followed, 
the most recent and comprehensive of which lists ca. 3,000 plant taxa 
(MECPAS, 2013) and served as one of the main sources of conservation 
assessment adopted throughout the Guide.  
4.4.2. Results 
Of the 302 official source species described in the Guide, 270 are native to 
China. Table 3 shows the breakdown of native species nationally threatened 
and the subset directly affected by medicinal over-harvesting.  Two species 
are ‘Extinct in the Wild’: Panax notoginseng and Prunus persica but the cause 
of their extinction is unclear. 61 species are directly threatened by over-
harvesting although this is not the sole threat to these species. 
4.4.3. Discussion 
To illustrate various conservation scenarios I can divide the 73 medicinal 
plant taxa that are nationally threatened into 3 main groups; these are not 
mutually exclusive: 
1. Genera ‘safe’ in medicinal cultivation (Eucommia, Dendrobium, Gastrodia, 
Glehnia, Paeonia, Phellodendron). A review of China’s National Plant 
Conservation Strategy states that of the approximately 600 mainstream TCM 
plants 200 have been brought into ‘sustainable cultivation’ (Huang, 2011). 
Their long-term security is in doubt if the genepools of their wild populations 
are not adequately conserved. Valuable traits required for future breeding 
programmes include disease resistance and adaption to climate change.  
Loss of germplasm variability will also limit the application of bioprospecting 
that benefits from traditional knowledge of medicinal plant use (Saslis-
Lagoudakisa et al., 2012). Examples of threatened TCM species which may 
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provide leads (along with their close phylogenetic relatives) for global disease 
conditions, notably cognitive disorders, include Coptis chinensis and Magnolia 
officinalis (source of ‘Hou Po – Magnoliae Officinalis Cortex’, Guide, pp. 508-
11) (Howes & Houghton, 2003).  
2. Those economically extinct (i.e. no longer economically viable for harvest 
due to their scarcity) and yet to be brought into commercial cultivation, such 
as Sophora tonkinensis (Guide, p.260). It is these species that are under 
greatest threat of extinction. Conservation work on some of these is 
underway (see below) but it is difficult to assess progress on other species 
because of the size of the country and number of species involved.  
Detecting unofficial substitutes of wild-harvested species can provide early 
warning of supply problems for that species, suggesting its populations are 
threatened by over-harvesting. Identification of such substitutes, as 
described throughout the Guide, can inform conservation agendas. For 
example, the two official source species of ‘Zi Cao’ (Arnebia euchroma and A. 
guttata; see Arnebiae Radix, Guide, pp.336-9) are both critically endangered 
due to over-harvesting, and ad-hoc trade studies demonstrate the regular 
occurrence of substitutes.  
3. Species whose wild populations have been the focus of recovery 
programmes (e.g. Cistanche deserticola, Fritillaria cirrhosa). F. cirrhosa 
(Guide, pp.78-85) has been the focus of a long-term and large-scale ‘natural 
fostering’ initiative to enable sustainable harvesting, however indiscriminate 
harvesting of the species in other parts of its range continues in order to 
meet demand. 
It is not clear whether the proportion of threatened CMM source species in 
the Guide is representative of CMM source species as a whole. This is 
because one of the criteria for the selection of CMM included in the Guide 
was CMM prone to substitution and, as discussed above, some substitutions 





Of the 302 official source species in the Guide 25% are declining nationally 
and fall into one of the IUCN threatened categories or are classified as Near 
Threatened. This problem has been recognised through national surveys (as 
cited above) and although a variety of conservation measures are in place for 
some of these species, there is an acute need for an in depth strategic 
programme for their conservation and sustainable sourcing (Chen et al., 
2016; Huang, 2011). 
 
5. CONCLUSIONS AND FUTURE DIRECTIONS 
This research demonstrates that the macroscopic approach can reliably 
identify crude and processed drugs of many TCM species. Macroscopy 
provides a fast and cost-effective method both to authenticate a drug’s 
identity and to discriminate it from common unofficial substitutes. Where 
macroscopy is considered insufficiently robust for the drugs included in the 
Guide, laboratory-based methods are recommended but their availability in 
contexts such as markets and dispensaries is limited by practical 
considerations.  
The routine use of verified drug reference materials is becoming increasingly 
widely recognised as essential by the many disciplines reliant on accurate 
herbal drug identity. The creation of these reference resources is however 
hugely time and labour-intensive and accordingly very few such resources 
exist; a recent Sino-American collaboration provides a recent example 
(Eisenberg et al., 2011). The reference collections underpinning the Guide 
demonstrate how international collaborations can deliver such resources. 
Where traceability to source plants is possible, their identification provides 
the ultimate proof of a drug’s identity, hence the emphasis placed on living 
plants as well as drugs throughout the Guide.  
The disconnect between the TCM community and its botanical counterpart 
hinders transfer of taxonomic knowledge, and its impact is visible in the use 
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of ambiguous and outdated names in, for example, the Chinese 
Pharmacopoeia. Inaccuracies tend to be perpetuated throughout the herbal 
literature due to lack of good practice. Solutions include improved dialogue 
between these communities and standardised nomenclatures that link TCM 
names to accepted Latin botanical names. The work involved in the Guide 
illustrates that this knowledge transfer cannot be automated, but relies upon 
time-consuming interactions between relevant specialists.  
Highlighted throughout are those TCM drugs most likely to be substituted in 
international trade. The occurrence of substitutes is an expression of clinical 
preference, confused identifications and nomenclatures, dispensary 
availability, unscrupulous trading as well as early warning of declining wild 
populations. These factors underline the importance of plant and herbal drug 
identification and which in turn impact efficacy, safety and sustainable 
supply.  
The Guide, and the approach it takes, aims to encourage a more considered 
approach to plant and drug identification. It is not enough to apply 
identification criteria in isolation; other factors such as likelihood of 
substitution must be taken into account. Ultimately this approach will lead to 
improvements in clinical practice, better framed herbal medicine and 





Table 1: Types of Chinese materia medica (CMM) name 
CMM name type Example 1 (CMM officially 
sourced from 1 species & 1 
processed trade type) 
Example 2  (CMM officially 
sourced from 3 species & 3 





plus plant part) 
Scrophulariae Radix (or Radix 
Scrophulariae) 
Coptidis Rhizoma (or Rhizoma 
Coptidis) 
Chinese name in 
simplified 
characters 
玄参 黄连 (酒黄连; 姜黄连; 萸黄连) 
Chinese name in 
traditional 
characters 
玄參 黃連 (酒黃連;  薑黃連; 萸黃連) 
Pin Yin name(s) Xuan Shen  Huang Lian (Jiu Huang Liang - wine 
processed; Jian Huang Liang - 
ginger-processed); Yu Huang Liang 
- processed with Tetradium 
ruticarpum fruits)  




figwort root golden thread 
Latin scientific 
name of source 
species &plant 
part 
Scrophularia ningpoensis Hemsl. - 
root 
Coptis chinensis Franch.; C. 
deltoidea C. Y. Cheng & P. K. 
Hsiao; C. teeta Wall. - root 
 
Table 2: Causes of substitution 
 
  No. species 
substitutions 
    
clinical similarity/interchangeable use  48 
supply problems  18 
mis-identification at point of harvest 15 
confused Chinese trade nomenclature  2 
cheaper morphological look-alikes for high-value drugs   2 





Table 3: CP2015 threatened plant species in the Guide (n=270) according to  
 IUCN categories. 





Extinct in the wild (EW) 2 2 
Threatened & declining 
(Critically Endangered (CR); 
Endangered (EN); Vulnerable 
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